Literature DB >> 8616094

Inhibition of platelet adhesion to collagen by monoclonal anti-CD36 antibodies.

K Matsuno1, M Diaz-Ricart, R R Montgomery, R H Aster, G A Jamieson, N N Tandon.   

Abstract

Monoclonal anti CD36 antibodies capable of inhibiting platelet adhesion to collagen have not previously been identified. We have now prepared two groups of monoclonal antibodies. One group was prepared using, as immunogen, highly purified (99+%) CD36 prepared by a denaturing procedure. These antibodies (Mo series) reacted strongly with CD36 on protein blots but did not immunoprecipitate native CD36 from platelet lysates nor inhibit platelet adhesion to collagen. The second group of monoclonal antibodies (131 series) was prepared using CD36 purified to >95% by a non-denaturing procedure. These antibodies reacted with control platelets, but not Nak(a)-negative platelets which lack CD36, as measured by flow cytometry and immunoprecipitation. Three monoclonal antibodies of this latter group (131.4, 131.5 and 131.7) inhibited platelet adhesion to collagen in static systems under Mg2+ -independent conditions but had lit tle effect in the presence of Mg2+. 131.4 and 131.7 also inhibited adhesion to collagen using citrated whole blood in a parallel plate flow chamber at physiological shear rates (800s-1), whereas 131.5 was without effect. These are the first anti-CD36 monoclonal antibodies shown to be capable of inhibiting platelet adhesion to collagen and provide further evidence that CD36 plays a role in platelet-collagen interaction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616094     DOI: 10.1046/j.1365-2141.1996.422962.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Tissue-specific and fatty acid transporter-specific changes in heart and soleus muscle over a 1-yr period.

Authors:  Arend Bonen; James G Nickerson; Iman Momken; Adrian Chabowski; Jorge Calles-Escandon; Narendra N Tandon; Jan F C Glatz; Joost J F P Luiken
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

2.  Prolonged AMPK activation increases the expression of fatty acid transporters in cardiac myocytes and perfused hearts.

Authors:  Adrian Chabowski; Iman Momken; Susan L M Coort; Jorge Calles-Escandon; Narendra N Tandon; Jan F C Glatz; Joost J F P Luiken; Arend Bonen
Journal:  Mol Cell Biochem       Date:  2006-05-19       Impact factor: 3.396

3.  A sensitive immunoassay for rat fatty acid translocase (CD36) using phage antibodies selected on cell transfectants: abundant presence of fatty acid translocase/CD36 in cardiac and red skeletal muscle and up-regulation in diabetes.

Authors:  M M Pelsers; J T Lutgerink; F A Nieuwenhoven; N N Tandon; G J van der Vusse; J W Arends; H R Hoogenboom; J F Glatz
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

4.  Formation of one or more intrachain disulphide bonds is required for the intracellular processing and transport of CD36.

Authors:  P Gruarin; R Sitia; M Alessio
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

5.  Surface expression of fatty acid translocase (FAT/CD36) on platelets in myeloproliferative disorders and non-insulin dependent diabetes mellitus: effect on arachidonic acid uptake.

Authors:  Hasib Salah-Uddin; Margaret J Gordon; Isobel Ford; Narendra N Tandon; Mike Greaves; Asim K Duttaroy
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

Review 6.  Exercise- and training-induced upregulation of skeletal muscle fatty acid oxidation are not solely dependent on mitochondrial machinery and biogenesis.

Authors:  Yuko Yoshida; Swati S Jain; Jay T McFarlan; Laelie A Snook; Adrian Chabowski; Arend Bonen
Journal:  J Physiol       Date:  2012-08-13       Impact factor: 5.182

7.  Greater transport efficiencies of the membrane fatty acid transporters FAT/CD36 and FATP4 compared with FABPpm and FATP1 and differential effects on fatty acid esterification and oxidation in rat skeletal muscle.

Authors:  James G Nickerson; Hakam Alkhateeb; Carley R Benton; James Lally; Jennifer Nickerson; Xiao-Xia Han; Meredith H Wilson; Swati S Jain; Laelie A Snook; Jan F C Glatz; Adrian Chabowski; Joost J F P Luiken; Arend Bonen
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

8.  Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria.

Authors:  Carley R Benton; Graham P Holloway; S E Campbell; Yuko Yoshida; Narendra N Tandon; Jan F C Glatz; Joost J J F P Luiken; Lawrence L Spriet; Arend Bonen
Journal:  J Physiol       Date:  2008-01-31       Impact factor: 5.182

9.  Purification, immunochemical quantification and localization in rat heart of putative fatty acid translocase (FAT/CD36).

Authors:  Joep F F Brinkmann; Maurice M A L Pelsers; Frans A van Nieuwenhoven; Narendra N Tandon; Ger J van der Vusse; Jan F C Glatz
Journal:  Mol Cell Biochem       Date:  2006-03-16       Impact factor: 3.396

10.  Exosome poly-ubiquitin inhibits platelet activation, downregulates CD36 and inhibits pro-atherothombotic cellular functions.

Authors:  S Srikanthan; W Li; R L Silverstein; T M McIntyre
Journal:  J Thromb Haemost       Date:  2014-10-13       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.